BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Global Blood Therapeutics 

455 Mission Bay Blvd South
Suite 575
San Francisco  California  94158  U.S.A.
Phone: 415-766-3600 Fax: n/a


SEARCH JOBS



Global Blood Therapeutics is developing novel, orally-available therapeutics designed to change the treatment paradigm for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options.

The current standard of care treats the symptoms during acute episodes; however, the underlying pathology of the disease causes progressive damage to the body. Global Blood Therapeutics is focused on the critical need for therapeutics that address the causes of blood diseases, not just the symptoms.

Global Blood Therapeutics’ extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics.

The Company has built a pipeline of preclinical programs focused on several blood diseases. Its lead program is in sickle cell disease, a global health challenge with very limited treatment options and none that address the underlying cause of the disease. The Company’s pipeline also includes a novel therapeutic for hereditary angioedema.

Global Blood Therapeutics is a private Company led by an experienced management team with a track record of four successful drug approvals and more than 30 investigational new drug applications. Backed by Third Rock Ventures, the Company was founded in 2012 with a $40.7 million Series A financing.


 Key Statistics


Email: info@globalbloodtx.com
Ownership: Private

Web Site: Global Blood Therapeutics
Employees: n/a
Symbol: 
 



Industry
Biotechnology






 Company News
Global Blood Therapeutics' GBT440 Demonstrates Ability To Positively Impact Fundamental Sickle Cell Disease (SCD) Processes In Studies Presented At 2014 American Society of Hematology Conference 12/8/2014 11:40:59 AM
Global Blood Therapeutics To Present New Data Highlighting Therapeutic Potential Of GBT440 In Sickle Cell Disease (SCD) At 2014 American Society of Hematology Conference 12/3/2014 2:29:27 PM
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
Global Blood Therapeutics Names Hing Sham Senior Vice President Of Chemistry, Promotes Uma Sinha To Chief Scientific Officer 8/4/2014 10:04:53 AM
Global Blood Therapeutics Names Ted W. Love As CEO 6/17/2014 10:00:03 AM
Global Blood Therapeutics to Present First Data on its Lead Sickle Cell Disease Program at 55th American Society of Hematology Annual Meeting 11/7/2013 8:42:00 AM
Global Blood Therapeutics Appoints Ted W. Love, M.D., to the Company’s Board of Directors 9/19/2013 6:37:00 AM
Array BioPharma, Inc. (ARRY) and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology 3/6/2013 9:10:18 AM
Global Blood Therapeutics, Third Rock Ventures’s First West Coast Startup, Gets $41 Million 6/14/2012 7:55:05 AM